Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Expression Therapeutics LLC currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This indicates that each pending case is being reviewed by a different examiner in a different technical classification.
The busiest examiner for this company is MELCHIOR, JAMES RYLAND, who is responsible for 1 pending office action. Since there are 3 pending office actions in total, each of the 3 distinct examiners is handling a case. This distribution means that the company's prosecution workload is balanced among the assigned examiners.
Practitioners must navigate 3 distinct art units, each potentially having its own examination standards. With 3 pending office actions spread across 3 distinct examiners, the company faces a highly decentralized prosecution environment. Success in the Biotechnology & Pharmaceuticals portfolio requires managing 3 separate interactions simultaneously, as the active cases are spread across multiple examiners and art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| DESAI, ANAND U | 1 | 78.5% | +12.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927078 | Lentiviral System | MATALKAH, FATIMAH KHALAF | 17d overdue |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | DESAI, ANAND U | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18095484 | Engineered T Cells | MELCHIOR, JAMES RYLAND | 140d overdue |
| 17927078 | Lentiviral System | MATALKAH, FATIMAH KHALAF | 17d overdue |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | DESAI, ANAND U | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1638 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18095484 | Engineered T Cells | MELCHIOR, JAMES RYLAND | 1644 | §103§112DP | Non-Final OA | 140d overdue | Pending | Jan 10, 2023 |
| 17927078 | Lentiviral System | MATALKAH, FATIMAH KHALAF | 1638 | §102§103 | Non-Final OA | 17d overdue | Pending | Nov 22, 2022 |
| 17632222 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE | DESAI, ANAND U | 1655 | §102§103§112Other | Final Rejection | — | Pending | Feb 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial